Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun 2;43(1):51.
doi: 10.1186/s13052-017-0368-6.

Current role of perampanel in pediatric epilepsy

Paola De Liso  1 , Romina Moavero  2   3 , Giangennaro Coppola  4 , Paolo Curatolo  5 , Raffaella Cusmai  1 , Giovambattista De Sarro  6 , Emilio Franzoni  7 , Federico Vigevano  1 , Alberto Verrotti  8
Affiliations
Review

Current role of perampanel in pediatric epilepsy

Paola De Liso et al. Ital J Pediatr. .

Abstract

Perampanel is among the latest AEDs approved, indicated for the treatment of partial-onset seizures with or without secondary generalization, and for primary generalized tonic-clonic seizures, in patients aged 12 years and older. This paper summarizes the clinical recommendations on the current role of perampanel in the treatment of pediatric epilepsies and future directions for research. The optimal dosage should be comprised between 4 and 12 mg/day, with 8 mg/day being the most common dosage used. The rate and severity of adverse events, including psychiatric symptoms, can be decreased by starting at low doses, and titrating slowly. Overall, perampanel presents an acceptable risk/benefit ratio, but special caution should be made to the risk of seizure aggravation and behavioral problems. The favorable cognitive profile, the ease of use of the titration scheme and the once-daily formulation offer advantage over other AEDs and make this drug particularly suitable for adolescent population. Perampanel is a welcome addition to the armamentarium of the existing AEDs, as it represents a new approach in the management of epilepsy, with a novel mechanism of action and a potential to have a considerable impact on the treatment of adolescents with epilepsy.

Keywords: AMPA; Antiepileptic drugs; Efficacy; Pediatric epilepsy; Perampanel; Tolerability.

PubMed Disclaimer

References

    1. Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord: Int Epilepsy J Videotape. 2015;17(2):117–123. - PubMed
    1. Zuberi SM, Symonds JD. Update on diagnosis and management of childhood epilepsies. J Pediatr. 2015;91(6 Suppl 1):S67–S77. doi: 10.1016/j.jped.2015.07.003. - DOI - PubMed
    1. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331–1340. doi: 10.1111/j.1528-1167.2011.03109.x. - DOI - PubMed
    1. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Suppl. 2013;197:19–24. doi: 10.1111/ane.12100. - DOI - PMC - PubMed
    1. Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta neurologica Scandinavica Supplementum. 2013(197):9-18. - PMC - PubMed